A subtle play on the idiom "Breath Easy" known as a suggestion to relax became central to Aeon Respire's Brand.  Indeed, their research in broad spectrum treatments for lung disease indications shows promise for severe asthma, Idiopathic Pulmonary Fibrosis (IPF), Pulmonary Arterial Hypertension (PAH), Chronic Obstructive Pulmonary Disease (COPD) and viral and bacterial lung infections.  Funded primarily from a NIH grant their lean team had discovered a treatment developed in the 1950s for parasitic infections was a perfect fit for pulmonary disorders.  Their main innovation was transforming the molecule into a targeting strategy creating both a novel treatment formulation and delivery technology, putting them in the first in class category for these deadly and debilitating lung born maladies.